Can a drug make radiation work better against aggressive brain tumors?
NCT ID NCT00209989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug ZARNESTRA to standard radiation therapy can slow tumor growth in people with glioblastoma, an aggressive brain cancer. Twenty-seven patients took the drug daily starting a week before radiation and continuing through treatment. The main goal was to see how long it took for the cancer to progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZARNESTRA (a drug that may make cancer cells more sensitive to radiation)
What this could lead to
If it works, this could point toward a way to slow glioblastoma progression by combining a drug with standard radiation.
What could go wrong
This is a small, early-phase study (27 people) with no control group, so results may not be conclusive. The drug may not improve outcomes or could add side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Jean Perrin
Clermont-Ferrand, France
-
Institut Claudius Regaud
Toulouse, France